2021年07月22日讯 /生物谷BIOON/ --Octapharma USA公司近日宣布，美国食品和药物管理局（FDA）已批准Octagam 10%（静脉注射免疫球蛋白 ...

瑞士拉亨--(BUSINESS WIRE)--(美国商业资讯)--Octapharma今天宣布，《新英格兰医学杂志》发表了关于octagam ® 10% [静脉注射免疫球蛋白（人类）]在成人皮肌炎患者中的疗效和安全性的ProDERM研究结果（Aggarwal R等，“Efficacy and safety of intravenous immunoglobulin in ...

HOBOKEN, N.J.--(BUSINESS WIRE)--Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human) 10% (100 mg/mL) Liquid ...

( )--Octapharma announced today the results from the ProDERM study on the efficacy and safety of octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been ...

Octapharma USA today announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octagam ® 10% [Immune ...

PARAMUS, N.J. (May 20, 2020) - The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on ...

Product Expected to Be Available for Distribution in a Few Weeks HOBOKEN, N.J. (November 4, 2011) - The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of ...

The first trial of this IVIG preparation in Alzheimer's evaluated six different doses of Octagam 10 percent against two placebo comparators in a six-month trial of 58 people with mild to moderate AD.

The Company has decided in conjunction with the FDA to suspend further administration of Octagam 10% from these specific production lots. Octapharma has initiated a voluntary market withdrawal of ...